We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , AbbVie Inc. (ABBV - Free Report) , NextEra Energy, Inc. (NEE - Free Report) , The Boeing Co. (BA - Free Report) and Canadian Natural Resources Ltd. (CNQ - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for JPMorgan, AbbVie and NextEra Energy
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., AbbVie Inc. and NextEra Energy, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of JPMorgan Chase have outperformed the Zacks Banks - Major Regional industry and the broader market over the past year (+0.9% vs. -16.7% for the industry and -8.2% for the S&P 500 index). The stock has lagged the broader market as well as the industry over the past month or so since the banking problems took center stage.
The stock was up in response to the last quarterly release on January 13th when the company handily beat estimates and provided reassuring commentary on broader business trends. Ahead of Q1 earnings release before the market's open this Friday (April 14th), estimates have largely been unchanged. A lot will be riding on management's characterization of business conditions following the Silicon Valley episode.
Higher rates and a steady loan demand are expected to have aided net interest income (NII) growth in the Q1 report. Yet, the volatile nature of the capital markets business and higher mortgage rates are likely to have made fee income growth challenging. We expect non-interest income (managed) to be relatively stable this year.
However, steadily rising costs is a major woe, and we expect the same to rise 5.8% in 2023. Given the possibility of an economic slowdown, provisions are likely to keep rising, with we projecting the same to jump 53.1% in 2023.
AbbVie shares have gained +4.5% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +7.5%. The company has several new drugs in its portfolio that have the potential to drive the top line to make up for lost Humira revenues. Skyrizi and Rinvoq have established outstanding launch trajectories bolstered by the approval of new indications.
It has several early/mid-stage candidates that have blockbuster potential. However, there are concerns about long-term sales growth since Humira generics have entered the U.S. market. Slowing consumer demand due to economic pressure is hurting the aesthetics franchise's sales.
Nonetheless, though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025. Estimates have declined ahead of Q1 earnings. AbbVie has a positive record of earnings surprises in recent quarters.
Shares of NextEra Energy have gained +8.4% over the past six months against the Zacks Utility - Electric Power industry's gain of +13.7%. The company continues to expand its operations through the efficient execution of organic projects and strategic acquisitions. The company currently has many renewable projects in its backlog and their completion will ensure reduced emissions.
The merger of Gulf Power and FPL strengthens NextEra's position in Florida. FPL's customer base is expanding as Florida's economy improves and continues to boost demand for its services. NextEra has ample liquidity to meet its near-term debt obligations and efficient debt management acting as tailwinds. Its shares have lost narrower than industry in the past one year.
However, the nature of its business is subject to complex federal, state and other regulations. Risk in operating nuclear units, unfavorable weather conditions and an increase in supply costs adversely impact earnings.
Other noteworthy reports we are featuring today include The Boeing Co. and Canadian Natural Resources Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources
For Immediate Release
Chicago, IL – April 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , AbbVie Inc. (ABBV - Free Report) , NextEra Energy, Inc. (NEE - Free Report) , The Boeing Co. (BA - Free Report) and Canadian Natural Resources Ltd. (CNQ - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for JPMorgan, AbbVie and NextEra Energy
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., AbbVie Inc. and NextEra Energy, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of JPMorgan Chase have outperformed the Zacks Banks - Major Regional industry and the broader market over the past year (+0.9% vs. -16.7% for the industry and -8.2% for the S&P 500 index). The stock has lagged the broader market as well as the industry over the past month or so since the banking problems took center stage.
The stock was up in response to the last quarterly release on January 13th when the company handily beat estimates and provided reassuring commentary on broader business trends. Ahead of Q1 earnings release before the market's open this Friday (April 14th), estimates have largely been unchanged. A lot will be riding on management's characterization of business conditions following the Silicon Valley episode.
Higher rates and a steady loan demand are expected to have aided net interest income (NII) growth in the Q1 report. Yet, the volatile nature of the capital markets business and higher mortgage rates are likely to have made fee income growth challenging. We expect non-interest income (managed) to be relatively stable this year.
However, steadily rising costs is a major woe, and we expect the same to rise 5.8% in 2023. Given the possibility of an economic slowdown, provisions are likely to keep rising, with we projecting the same to jump 53.1% in 2023.
(You can read the full research report on JPMorgan here >>>)
AbbVie shares have gained +4.5% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +7.5%. The company has several new drugs in its portfolio that have the potential to drive the top line to make up for lost Humira revenues. Skyrizi and Rinvoq have established outstanding launch trajectories bolstered by the approval of new indications.
It has several early/mid-stage candidates that have blockbuster potential. However, there are concerns about long-term sales growth since Humira generics have entered the U.S. market. Slowing consumer demand due to economic pressure is hurting the aesthetics franchise's sales.
Nonetheless, though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025. Estimates have declined ahead of Q1 earnings. AbbVie has a positive record of earnings surprises in recent quarters.
(You can read the full research report on AbbVie here >>>)
Shares of NextEra Energy have gained +8.4% over the past six months against the Zacks Utility - Electric Power industry's gain of +13.7%. The company continues to expand its operations through the efficient execution of organic projects and strategic acquisitions. The company currently has many renewable projects in its backlog and their completion will ensure reduced emissions.
The merger of Gulf Power and FPL strengthens NextEra's position in Florida. FPL's customer base is expanding as Florida's economy improves and continues to boost demand for its services. NextEra has ample liquidity to meet its near-term debt obligations and efficient debt management acting as tailwinds. Its shares have lost narrower than industry in the past one year.
However, the nature of its business is subject to complex federal, state and other regulations. Risk in operating nuclear units, unfavorable weather conditions and an increase in supply costs adversely impact earnings.
(You can read the full research report on NextEra Energy here >>>)
Other noteworthy reports we are featuring today include The Boeing Co. and Canadian Natural Resources Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.